1型糖尿病单独或肾移植后胰岛移植的十年结局:前瞻性平行组队列研究
该前瞻性平行组队列研究纳入28例1型糖尿病伴低血糖感知受损和/或肾功能良好的肾移植受者,接受单独胰岛移植(ITA)或肾移植后胰岛移植(IAK)。主要结局为不依赖胰岛素且A1C≤6.5%,5年和10年分别有39%和28%患者达标;移植物功能5年和10年分别维持在82%和78%,且与血糖控制改善、外源胰岛素需求减少和严重低血糖事件显著减少相关。
要点
- 胰岛移植后5年和10年不依赖胰岛素且A1C≤6.5%的比例分别为39%和28%。
- 移植物功能5年和10年分别维持在82%和78%,ITA与IAK结局相似。
- 移植后1个月的原发移植物功能与移植物功能持续时间和胰岛素不依赖显著相关。
核心结论
- 采用Edmonton方案的胰岛移植可在四分之三的1型糖尿病患者(无论是否接受肾移植)中提供10年显著改善的代谢控制且无严重低血糖事件。
研究设计与样本
- 前瞻性平行组队列研究,纳入28例1型糖尿病伴低血糖感知受损和/或肾功能良好的肾移植受者,接受单独胰岛移植(ITA)或肾移植后胰岛移植(IAK)。
- 胰岛移植包括2或3次门静脉内同种异体胰岛输注,中位间隔68天(43-92)。
- 免疫抑制采用白细胞介素-2受体抗体诱导,西罗莫司和他克莫司维持。
主要发现
- 主要结局(不依赖胰岛素且A1C≤6.5%)5年和10年达标率分别为39%(95%CI 22-57)和28%(95%CI 13-45)。
- 移植物功能5年和10年持续率分别为82%(95%CI 62-92)和78%(95%CI 57-89),与血糖控制改善、外源胰岛素需求减少和严重低血糖事件显著减少相关。
- ITA和IAK结局相似。
- 最后一次胰岛输注后1个月评估的原发移植物功能与移植物功能持续时间和胰岛素不依赖显著相关。
临床怎么用
- 对于1型糖尿病伴低血糖感知受损和/或肾功能良好的肾移植受者,可考虑采用Edmonton方案的胰岛移植以改善长期代谢控制并减少严重低血糖事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The long-term outcome of allogenic islet transplantation is unknown. The aim of this study was to evaluate the 10-year outcome of islet transplantation in patients with type 1 diabetes and hypoglycemia unawareness and/or a functioning kidney graft. RESEARCH DESIGN AND METHODS: We enrolled in this prospective parallel-arm cohort study 28 subjects with type 1 diabetes who received islet transplantation either alone (ITA) or after a kidney graft (IAK). Islet transplantation consisted of two or three intraportal infusions of allogenic islets administered within (median [interquartile range]) 68 days (43-92). Immunosuppression was induced with interleukin-2 receptor antibodies and maintained with sirolimus and tacrolimus. The primary outcome was insulin independence with A1C ≤6.5% (48 mmol/mol). Secondary outcomes were patient and graft survival, severe hypoglycemic events (SHEs), metabolic control, and renal function. RESULTS: The primary outcome was met by (Kaplan-Meier estimates [95% CI]) 39% (22-57) and 28% (13-45) of patients 5 and 10 years after islet transplantation, respectively. Graft function persisted in 82% (62-92) and 78% (57-89) of case subjects after 5 and 10 years, respectively, and was associated with improved glucose control, reduced need for exogenous insulin, and a marked decrease of SHEs. ITA and IAK had similar outcomes. Primary graft function, evaluated 1 month after the last islet infusion, was significantly associated with the duration of graft function and insulin independence. CONCLUSIONS: Islet transplantation with the Edmonton protocol can provide 10-year markedly improved metabolic control without SHEs in three-quarters of patients with type 1 diabetes, kidney transplanted or not.
引用
- Vantyghem MC, Chetboun M, Gmyr V, et al. Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study. Diabetes Care. 2019. PMID: 31615852. doi:10.2337/dc19-0401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。